Lila Nachtigall, MD


  • Professor, Department of Obstetrics and Gynecology
Education and Training
  • Residency, NYU Medical Center, Medicine (Internal), 1964
  • Fellowship, NYU Medical Center, Endocrinology, 1963
  • MD from New York Medical College, 1960

Locations and Appointments

251 East 33rd Street, 5th Floor
New York, NY 10016


Phone: 212-263-6361

Welcome back!

As a returning patient for this doctor, please schedule an appointment using your MyChart at NYU Langone account.

Learn more about MyChart at NYU Langone.

My Research

Over the past 20 years Lila E. Nachtigall, M.D. has been involved in three areas of investigation. These include: 1) evaluating whether estrogen replacement therapy (ERT) reduces the risk of coronary heart disease and other cardiovascular in women; 2) determining whether estrogen replacement alone or estrogen progesterone replacement reduces the incidence of osteoporosis-related fractures and hip fractures; and 3) whether ERT increases the risk of endometrial cancer and whether progestin and estrogen replacement therapies (PERT) increase breast cancer risk.

Studies in these specific areas have been ongoing at NYU Medical Center since 1967. Dr. Nachtigall conducted a comprehensive ten year prospective double blind placebo controlled study of estrogen replacement therapy and the relationship to carcinoma, cardiovascular disease, and osteoporosis in a sample of hospitalized women. From the 300 women recruited, 168 were followed as matched pairs. This study was the first to demonstrate the increased survival of patients on ERT, of lipid patterns as a significant risk factor, and of a reduction in breast cancer incidence in treated patients as compared to the controls. Moreover, a ten year follow-up with single photon densitometer measurements found continued increase in bone density in treated women who had their last menstrual period within three years or less, while those on placebo continued to lose bone. In addition, treated women who had their last menstrual period more than three years previously, kept their bone at a steady level, while their placebo controlled matched pairs continued to lose bone. Dr. Nachtigall subsequently conducted a 22 year follow-up on these studies, losing only five patients to follow-up or breast cancer.

Studies are continuing to address such issues as the efficacy of transdermal versus oral estrogen, the use of progesterone in prevention of endometrial cancer, the ability to decrease the side effects of progesterone therapy and on cardiovascular disease in older women, with and without hormones.


  • Is Percentile Body Fat by Dual-Energy X-Ray Absorptiometry a Better Surrogate for Metabolic Health Than Body Mass Index? [Meeting Abstract]

    Goldstein, Steven Robert; Nachtigall, Lila E; Nachtigall, Richard
    Obstetrics & gynecology. 2015 MAY. 125: 98S-99S

  • Hormone therapy and ovarian cancer [Letter]

    Naftolin, Frederick; Friedenthal, Jenna; Blakemore, Jennifer; Nachtigall, Lila
    Lancet. 2015 Sep. 386 (9998): 1037-1037

  • Hot flashes: is a hot flash just a hot flash?

    Nachtigall, Lila
    Menopause. 2014 Jun. 21 (6): 551-552

Read All Publications (112)